SCHEMBL6845448

SCHEMBL6845448

CC(=O)O[C@@]1(C)CCC2C3C=CC4=CC(=O)CC[C@]4(C)C3CC[C@@]21C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 4/20 0.62
PGR P06401 5/20 0.62
CYP3A4 P08684 4/20 0.62
AR P10275 3/20 0.62
ALDH1A1 P00352 2/20 0.62
CYP2C19 P33261 2/20 0.62
CHRM1 P11229 2/20 0.62
TBXA2R P21731 2/20 0.62
ADRA1A P35348 2/20 0.62
NR3C1 P04150 4/20 0.60
MEN1 O00255 4/20 0.60
KMT2A Q03164 4/20 0.60
CHRM2 P08172 2/20 0.60
OPRK1 P41145 1/20 0.60
TDP1 Q9NUW8 3/20 0.58
LMNA P02545 3/20 0.58
PDE4D Q08499 1/20 0.58
SMN1; SMN2 Q16637 3/20 0.53
CYP2C9 P11712 2/20 0.53
HIF1A Q16665 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6845447 1.00 CYP19A1 (0.62) CYP19A1PGRCYP3A4ARALDH1A1
SCHEMBL5925193 0.87 PGR (0.70) CYP19A1PGRCYP3A4ARALDH1A1
SCHEMBL149089 0.87 PGR (0.70) CYP19A1PGRCYP3A4ARALDH1A1
SCHEMBL19632528 0.85 PGR (0.58) CYP19A1PGRCYP3A4ARALDH1A1
SCHEMBL3934288 0.83 MEN1 (0.70) CYP19A1PGRCYP3A4ARALDH1A1
SCHEMBL3934282 0.83 MEN1 (0.70) CYP19A1PGRCYP3A4ARALDH1A1
SCHEMBL11648110 0.82 PGR (0.56) CYP19A1PGRCYP3A4ARALDH1A1
SCHEMBL3939910 0.82 PGR (0.67) CYP19A1PGRCYP3A4ARALDH1A1
SCHEMBL3939914 0.82 PGR (0.67) CYP19A1PGRCYP3A4ARALDH1A1
SCHEMBL8642981 0.81 CYP19A1 (0.70) CYP19A1PGRCYP3A4ARALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6767903-B1 ANTIANDROGEN THERAPY FOR PROSTATE CANCER SCHERING AG (DE) 2004-07-27 US disclosed